UA73738C2 - Naphtalene ureas as intensifier of glucose absorption - Google Patents

Naphtalene ureas as intensifier of glucose absorption Download PDF

Info

Publication number
UA73738C2
UA73738C2 UA2001129042A UA2001129042A UA73738C2 UA 73738 C2 UA73738 C2 UA 73738C2 UA 2001129042 A UA2001129042 A UA 2001129042A UA 2001129042 A UA2001129042 A UA 2001129042A UA 73738 C2 UA73738 C2 UA 73738C2
Authority
UA
Ukraine
Prior art keywords
amino
naphthyl
alkyl
sulfonyl
independently
Prior art date
Application number
UA2001129042A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA73738C2 publication Critical patent/UA73738C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA2001129042A 1999-05-26 2000-05-25 Naphtalene ureas as intensifier of glucose absorption UA73738C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13612899P 1999-05-26 1999-05-26
PCT/US2000/014644 WO2000071506A2 (fr) 1999-05-26 2000-05-25 Nouvelles naphtalene urees utiles en tant qu'activateurs de l'absorption du glucose

Publications (1)

Publication Number Publication Date
UA73738C2 true UA73738C2 (en) 2005-09-15

Family

ID=22471427

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001129042A UA73738C2 (en) 1999-05-26 2000-05-25 Naphtalene ureas as intensifier of glucose absorption

Country Status (26)

Country Link
US (2) US6458998B1 (fr)
EP (1) EP1181271B1 (fr)
JP (1) JP2003500381A (fr)
KR (1) KR100746870B1 (fr)
CN (1) CN1364156A (fr)
AR (1) AR024109A1 (fr)
AT (1) ATE287394T1 (fr)
AU (1) AU776438C (fr)
BR (1) BR0011550A (fr)
CA (1) CA2374225A1 (fr)
CZ (1) CZ20014153A3 (fr)
DE (1) DE60017554T2 (fr)
EA (1) EA006763B1 (fr)
ES (1) ES2233386T3 (fr)
HK (1) HK1046399A1 (fr)
HU (1) HUP0201306A3 (fr)
IL (2) IL146576A0 (fr)
MX (1) MXPA01012079A (fr)
NO (1) NO20015713L (fr)
NZ (1) NZ515743A (fr)
PL (1) PL352631A1 (fr)
TR (1) TR200103409T2 (fr)
TW (1) TWI234557B (fr)
UA (1) UA73738C2 (fr)
WO (1) WO2000071506A2 (fr)
ZA (1) ZA200109641B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7058589B1 (en) * 1998-12-17 2006-06-06 Iex Corporation Method and system for employee work scheduling
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Corporation Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001083431A1 (fr) * 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Inhibiteurs de mmp-12
ITTO20010950A1 (it) * 2000-10-11 2003-04-09 Telik Inc Attivatori di recettori di insulina per il trattamento di disturbi metabolici in esseri umani che risultano dal trattamento di infezioni da
US6528037B2 (en) 2000-10-11 2003-03-04 Telik, Inc. Method for determining whether a compound is an insulin receptor kinase activator
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
KR100989394B1 (ko) 2002-10-21 2010-10-25 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단 및 그 용도
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
EP1878734A4 (fr) 2005-04-28 2010-02-17 Ajinomoto Kk Nouveau composé lactame
AU2012200933B2 (en) * 2005-06-22 2015-04-30 Plexxikon, Inc. Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors
NZ565255A (en) * 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
AU2006287480B2 (en) 2005-09-09 2012-07-05 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
WO2011057022A1 (fr) 2009-11-06 2011-05-12 Plexxikon, Inc. Composés et méthodes de modulation des kinases et leurs indications d'emploi
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH488212A (de) * 1967-09-01 1970-03-31 Ciba Geigy Photographisches Material
CA987310A (en) * 1971-04-07 1976-04-13 Ciba-Geigy Ag Azo dyestuffs, their manufacture and use
US4118232A (en) * 1971-04-07 1978-10-03 Ciba-Geigy Ag Photographic material containing sulphonic acid group containing disazo dyestuffs
US4051176A (en) * 1976-05-10 1977-09-27 American Cyanamid Company Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds
US4129591A (en) * 1976-10-27 1978-12-12 American Cyanamid Company Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts
US4102917A (en) * 1977-06-01 1978-07-25 American Cyanamid Company Substituted phenyl naphthalenesulfonic acids
US4132730A (en) * 1977-07-29 1979-01-02 American Cyanamid Company Ureylene naphthalene sulfonic acids
US4120891A (en) * 1977-07-01 1978-10-17 American Cyanamid Company Ureylene naphthalene sulfonic acids
JPS58191772A (ja) * 1982-05-06 1983-11-09 Canon Inc 記録液及びこれを用いたインクジェット記録方法
US4591604A (en) * 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
DE19521589A1 (de) * 1995-06-14 1996-12-19 Bayer Ag Polyfunktionelle Azoreaktivfarbstoffe
US5830918A (en) * 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
ATE296446T1 (de) * 1997-01-15 2005-06-15 Telik Inc Modulatoren von insulinrezeptor-aktivität
US6140368A (en) * 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods

Also Published As

Publication number Publication date
JP2003500381A (ja) 2003-01-07
US20030135063A1 (en) 2003-07-17
AU776438B2 (en) 2004-09-09
IL146576A0 (en) 2002-07-25
NO20015713D0 (no) 2001-11-23
DE60017554D1 (de) 2005-02-24
WO2000071506A3 (fr) 2001-08-09
HUP0201306A2 (en) 2002-09-28
CA2374225A1 (fr) 2000-11-30
WO2000071506A9 (fr) 2001-09-20
US7071231B2 (en) 2006-07-04
TWI234557B (en) 2005-06-21
WO2000071506A2 (fr) 2000-11-30
EP1181271B1 (fr) 2005-01-19
AR024109A1 (es) 2002-09-04
DE60017554T2 (de) 2006-03-30
AU776438C (en) 2005-07-28
EA006763B1 (ru) 2006-04-28
HUP0201306A3 (en) 2005-04-28
KR100746870B1 (ko) 2007-08-07
EA200101231A1 (ru) 2002-06-27
NO20015713L (no) 2001-12-20
CZ20014153A3 (cs) 2002-05-15
NZ515743A (en) 2003-08-29
EP1181271A2 (fr) 2002-02-27
ATE287394T1 (de) 2005-02-15
TR200103409T2 (tr) 2002-05-21
KR20020022679A (ko) 2002-03-27
CN1364156A (zh) 2002-08-14
ZA200109641B (en) 2003-02-24
IL146576A (en) 2006-10-05
AU5168400A (en) 2000-12-12
PL352631A1 (en) 2003-08-25
HK1046399A1 (en) 2003-01-10
MXPA01012079A (es) 2003-06-30
BR0011550A (pt) 2002-06-04
ES2233386T3 (es) 2005-06-16
US6458998B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
UA73738C2 (en) Naphtalene ureas as intensifier of glucose absorption
AU2009253346B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
ES2966644T3 (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia
EP2018165B1 (fr) COMPOSES DIMERES AGONISTES DES RECEPTEURS DES FGFs
EP3983384B1 (fr) Dérivés de n-(phényl)-indole-3-sulfonamide et composés similares en tant que modulateurs du gpr17 pour le traitement de troubles du snc tels que sclérose en plaques
JP6665349B2 (ja) アシル化インスリン化合物
EA020959B1 (ru) Пептиды, специфичные к меланокортиновым рецепторам
US20240009169A9 (en) PPARG Modulators for the Treatment of Osteoporosis
JP2012519193A (ja) テトラヒドロ−イミダゾ［１，５−α］ピラジン誘導体塩、その製造方法及び医薬用途
CN110003104A (zh) 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
JP2020511494A (ja) Ｎｐｒａアゴニスト、組成物およびその使用
WO2019028357A1 (fr) Composés pour la prévention et le traitement de troubles médicaux et leurs utilisations
JP2008505161A (ja) 糖尿病の治療および／または予防用アリールアルキルアミンバナジウム（ｖ）塩
US6864267B2 (en) Calcilytic compounds
CN107820495A (zh) 靶向epha4的配体结合域的新型epha4抑制剂
ITTO20000745A1 (it) Nuovi acidi naftilsolfonici e composti ad essi correlati utli come agonisti dell'assorbimento del glucosio.
CA3181902A1 (fr) Mehodes de traitement ou de prevention de maladie renale chronique
DE60308862T2 (de) Verbindungen und zusammensetzungen zur behandlung von diabetes und erkrankungen, die mit diabetes in zusammenhang stehen
WO2023144736A1 (fr) Compositions pour la prévention ou le traitement de l'hypertension artérielle pulmonaire
CN104649937B (zh) 苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104592065B (zh) 卤代苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104610105B (zh) 烷基取代的苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104109147A (zh) 羟基脒基苯类衍生物及其制备方法和医药用途
AU2013263786A1 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
CN104628612A (zh) 一类腈基苯磺酰肼类gpr119激动剂、制备方法及其用途